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Background: Enterobacter is a common nosocomial microorganism and its carbapenem’s
resistance has increased. The management of these cases is unclear.
Objective: We evaluated 16 patients with KPC-producing Enterobacter aerogenes infections,
detailing the site of infection, therapy, clinical and epidemiological data.
Methods: A retrospective and descriptive study. Clinical data were revised and KPC-2 detec-
tion  was by molecular methods. Risk factors associated with mortality were compared using
appropriate tests according to variable type with a signiﬁcance level of 0.05.
Results: The 30-day mortality rate was 37.5% with no association with inadequate treatment.
Age  (p = 0.004) and Charlson score of comorbidities (p = 0.048) were independent risk factors
associated with death in the multivariate analysis. The odds ratio for age >43 years was
3.00  (95% CI: 1.02–9.32) and for Charlson score >3 was 2.00 (95% CI: 1.08–3.71). Five strains
were pan-resistant based on automated susceptibility tests. All patients were treated with
monotherapy.
Conclusion: The clinician should be alert to carbapenem-resistant Enterobacteriaceae infectionin  older patients with comorbidities. The mortality is high and we  believe that prompt and
adequate therapy must be employed.
© 2015 Elsevier Editora Ltda. All rights reserved.
emergence of carbapenemase-producing EnterobacteriaceaeEnterobacter is a microorganism associated with third
generation cephalosporins resistance due to overexpres-
sion of Amp-C gene. However, we have observed a
progressive decrease in susceptibility to fourth genera-
tion cephalosporin, suggesting increase of ESBL-producing
strains.1 ESBL-producing Enterobacter are usually susceptible
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ment of choice for severe infections. More  recently, the, Hospital Universitário Evangélico de Curitiba, Alameda Augusto
ritiba, Brazil.
has severely challenged antimicrobial therapy, since it con-
fers a distinct level of resistance to carbapenems.2 The most
common carbapenemase identiﬁed in the world was ﬁrst
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escribed in Klebsiella pneumoniae, which is called Klebsiella
neumoniae carbapenemase (KPC).3
KPC-producing Enterobactericeae are spreading throughout
he world, not only in K. pneumoniae, but also in Escherichia coli,
nterobacter, Citrobacter,  Serratia and others.2 KPC-producing
nterobacter has been described in some series of Enterobac-
eriaceae, and recently Satlin and Jenkins published a case of
PC-producing Enterobacter gergoviae infection in an immuno-
uppressed patient with a poor outcome despite adequate
herapy.4
Considering the importance of Enterobacter as a nosocomial
acteria and the current resistance panorama, we evaluated 16
atients with KPC-producing Enterobacter aerogenes infections,
etailing the site of infection, therapy, and epidemiological
ata.
This was a case-series study with 16 patients with E. aero-
enes infection who  received care between January 2013 and
eptember 2013 in a general tertiary hospital in Curitiba, Brazil
Hospital Universitario Evangelico de Curitiba). The hospital
as 660 beds and it is a reference center for trauma, burn, and
enal transplant.
E. aerogenes identiﬁcation and susceptibility tests were
erformed with Vitek 2 (Biomérieux, Marcy-LÉtoile, France)
ccording to the CLSI guidelines.5 Isolates showing reduced
usceptibility to ertapenem/meropenem were tested for
etection of production of carbapenemase using the mod-
ﬁed Hodge test (MHT).5 Isolates with positive MHT were
ubmitted to PCR for blaKPC using EasyQ KPC (Biomérieux,
arcy-LÉtoile, France) as previously described.6 The amplicon
as fully sequenced until 900 pb. Minimal inhibitory concen-
ration (MIC) for meropenem, tigecycline, and colistin was
etermined by E-test.7
KPC-producing Enterobacteriaceae isolates were examined
sing automated rep-PCR-based typing system (DivesiLabTM,
iomérieux, Athens, GA, USA).8 The results were analyzed
nd interpreted with the DiversiLab web-bases software using
earson Correlation method. Clonally related isolates were
eﬁned as those with ≥95% homology.
We evaluated Charlson comorbidity index score, age,
ength of hospitalization before bacteremia, and antibiotic
se during infection. The site infection criteria were deﬁned
ccording to the Brazilian Health Surveillance Agency.9
Continuous data were expressed as mean with standard
eviation of interquartile (25–75%). Frequencies were
xpressed as percentages. All data were stored using the
oftware Excel (Microsoft, New York, USA) and statistical
nalysis was performed using the software SPSS 16 (SPSS,
hicago, USA). Univariate analysis was performed separately
or each of the variables. p-Values were calculated using
he chi-square test or Fisher’s exact test for categorical
ariables and Student’s t-test or Wilcoxon rank-sum test
or continuous variables. Variables for which the p-value
as ≤0.10 in univariate analysis were included in a forward
tepwise logistic regression model. Variables were checked
or confounding and collinearity. A p-value of 0.05 was set as
he limit for acceptance or removal of the new terms in the
odel. Goodness-of-ﬁt was assessed by Hosmer–Lemeshow
est. All tests were two-tailed, and a p-value ≤0.05 was con-
idered signiﬁcant. Therapy was considered adequate when
he microorganism was susceptible to the drug tested.5;1 9(3):324–327 325
All strains were compatible with KPC-2 type. The data are
detailed in Table 1. The mean age was 56 years (IQ 25–75%:
39–75). The thirty-day mortality was 37.5%, and the global in-
hospital mortality was 62.5%.
Adequate therapy was prescribed for only seven patients
(43.7%). Adequate therapy was not associated with a better
outcome in univariate analysis. Age (p = 0.004) and Charlson
score of comorbidities (p = 0.048) were risk factors associated
with death, but not gender or site of infection. These two con-
tinuous variables were categorized in order to perform a binary
logistic regression. In the multivariate analysis, both risk fac-
tors were independently associated with death: age > 43 years
(odds ratio = 3.00; 95% conﬁdence interval (CI) 1.02–9.32) and
Charlson score >3 (odds ratio = 2.00; 95% CI 1.08–3.71).
All patients were treated with antibiotic monotherapy but
always with maximal dosage adjusted for renal function,
except tigecycline and polymyxin. Tigecycline was used with
doubled dose and the dose of polymyxin was 25,000–30,000 IU
every 12 h. Five strains were pan-resistant considering auto-
mated susceptibility tests. One strain had MIC  > 16 mg/L for
colistin, but 8 mg/L for meropenem MIC and 2 mg/L for tigecy-
cline.
In some infections, like urinary tract, it was hard to
differentiate colonization from infection. Thus, it was not pos-
sible to conclude that fosfomycin was effective in treating
KPC-producing Enterobacter, although this approach has been
described previously by our group.10
A patient was considered treated when the drug used was
active in vitro. However, recommendation for tigecycline in
ventilator-associated pneumonia was not possible based on
data presented in Table 1.
The repPCR identiﬁed two clones (Fig. 1) suggesting a clonal
dissemination among 12 patients. Only 12 strains were tested
because four samples were unavailable.
KPC enzymes in Enterobacteriaceae have become endemic
in many  regions worldwide, especially among K. pneumoniae
isolates in Brazil.6 The emergence of KPC among these bacte-
ria has severely challenged antimicrobial therapy, since they
confer high level resistance to all beta-lactams and distinct
levels of resistance to the carbapenems. Several retrospective
studies tried give support for combined therapy against KPC-
producing Enterobacteriaceae,  without consistent results.11 In
this study, we conﬁrmed that the outcome is determined by
conditions other than adequate therapy. Advanced age was
an independent risk factor for KPC-producing Enterobacteri-
aceae in a previous study,6 but not a risk factor for mortality.
Fosfomycin has been used for severe infection, as urinary
tract infection in our service, but resistance has increased
as previously reported.10 Clinical breakpoints have not been
established for fosfomycin, but some authors have used the
same values established for E. coli, although these values are
off label.10
Clinicians should reevaluate the aggressive therapy (sev-
eral combinations and large dosages) in patients with
advanced age with several comorbidities, once adequate
therapy may not be sufﬁcient to modify the outcome.
The most important side effect of current therapies
against carbapenem-resistant Enterobacteriaceae (polymyxin
and aminoglycosides) is renal failure. Acute renal failure
increases mortality by 40%, a percentage that can outweigh
326
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Table 1 – Clinical data of 16 patients with KPC-producing Enterobacter aerogenes.
Gender Age Admission Survival Outcome Charlson
index
Source of
infection
Treatment Tigecycline
MIC (mg/L)c
Meropenem
MIC (mg/L)c
Colistin MIC
(mg/L)c
Treatment
F 82 21 1 Death 1 Surgical site infection Not treated 2 8 >16 None
F 54 214 88 Death 0 Ventilator pneumonia Treated 4 8 <0.5 Tigecycline 100 mg q12h 14d
F 58 33 35 Death 5 Urinary Not treated 4 >16 0.5 Meropenem 1000 mg q12h 4d
M 76 26 30 Death 4 Urinary Treated >8 >16 <0.5 Fosfomycin 3 g/day 17d
F 38 11 18 Survival 0 Ventilator pneumonia Not treated 4 8 4 Meropenem 500 mg q8h 11da
F 91 100 48 Death 6 Ventilator pneumonia Treated 4 1 4 Tigecycline 100 mg q12h 11d
M 23 0 70 Survival 0 Surgical site infection Not treated 4 >16 8 Tigecycline 100 mg q12 24d
M 90 25 1 Death 9 Blood Treated 4 >16 2 Polymyxin B 1,000,000 q12 3d (died)
F 50 9 8 Death 2 Blood Treated 4 >16 >16 Polymyxin B 1,000,000 q6h 8d
M 74 35 19 Death 5 Ventilator pneumonia Treated 4 >16 >16 Polymyxin B 1,000,000 q12h 14d
M 51 58 43 Survival 1 Catheter Not treated 4 >16 >16 Ampicillin/sulbactam 3 q6h 15d
M 30 8 8 Survival 0 Urinary Treated b Fosfomycin 3 g/day 7d
M 43 34 13 Death 0 Blood Not treated 4 >16 >16 Tigecycline 100 mg q12h 14d
M 31 34 28 Survival 0 Catheter Not treated 4 >16 >16 None
F 55 87 27 Survival 3 Urinary Not treated b Meropenem 1000 mg q8h 4d
M 51 54 0 Death 2 Ventilator pneumonia Not treated 1 8 0.5 Ciproﬂoxacin 400 mg q12h 10d
See full text for treatment discussion.
a Dosage adjusted to creatinine clearance.
b The sample was not stored.
c E-test.
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Fig. 1 – repPCR of 12 strains of KPC-producing Enterobacter
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he beneﬁts of therapy. This issue is controversial, but the
linician should be alert to carbapenem-resistant Enterobac-
eriaceae infection in immunosuppressed patients, as well as
n older patients with comorbidities. The mortality is high
nd we  believe that prompt and adequate therapy must be
mployed.
Despite uncertainty regarding the ideal treatment, infec-
ion control measures are fundamental to avoid spread
f these bacteria in the hospital. Our study showed two
lones out 16 strains. This suggests that cross-infections
ere responsible for this outbreak. From September through
ecember, Enterobacter producing KPC were not identiﬁed in
he hospital. Infection control measures were not employed
peciﬁcally to this microorganism, suggesting a self-limited
utbreak.
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